Genetics not found to influence Cosentyx treatment responses
The responses to Cosentyx (secukinumab) among people with ankylosing spondylitis (AS) and other inflammatory diseases aren’t significantly impacted by a person’s genetic background, a recent study suggests. The findings challenge an existing hypothesis that the variable responses to the therapy in clinical practice could largely be driven by…